If you want to make profit with us, just like us on facebook and join our membership at a very low cost. You can contact us atspecialpennystockalert.com@gmail.com. We are offering the new subscriber a special pricing offer at a deep discount for the first 100 joiners.
It’s not yet over, if you want to be in for our next winners join our paid membership at a very reasonable price now. You can contact us mailto:atspecialpennystockalert.com@gmail.com
]]>Get the Inside Scoop On IRT here with this Free Report
NQ Mobile Inc. (ADR) (NYSE:NQ)’s shares decreased 1.80% to $4.36. The company on July 9 responded to Muddy Waters’ report dated July 7, 2014. The Company fully respects the right of any third party to express its opinion but reminds investors that facts are facts. The independent investigation was overseen by a Special Committee of independent directors, and conducted by two highly respected firms with well-established reputations for integrity, Shearman & Sterling LLP, and Deloitte & Touche Financial Advisory Services Limited. It did not find any evidence that the Company had engaged in the fraudulent conduct alleged by Muddy Waters.
You won’t believe what we found out about NQ
ZipRealty, Inc.(NASDAQ:ZIPR)’s shares soared 121.81% and closed at $6.70. Harwood Feffer LLP (www.hfesq.com) on July 16 is investigating potential claims against the board of directors of ZipRealty, Inc. (“ZipRealty” or the “Company”) (ZIPR) concerning the proposed acquisition of the Company by Realogy Holdings Corp. (“Realogy”). Under the terms of the transaction, Realogy will purchase ZipRealty in a transaction valued at approximately $166 million. ZipRealty shareholders will receive $6.75 cash for each share of ZipRealty owned.
Why Should You Buy ZIPR Now? Get The Free Trend Analysis Here
]]>Get the Inside Scoop On CDXS here with this Free Report
NQ Mobile Inc. (ADR) (NYSE:NQ)’s shares decreased 1.55% to $4.44. The company on July 9 responded to Muddy Waters’ report dated July 7, 2014. The Company fully respects the right of any third party to express its opinion but reminds investors that facts are facts. The independent investigation was overseen by a Special Committee of independent directors, and conducted by two highly respected firms with well-established reputations for integrity, Shearman & Sterling LLP, and Deloitte & Touche Financial Advisory Services Limited. It did not find any evidence that the Company had engaged in the fraudulent conduct alleged by Muddy Waters.
You won’t believe what we found out about NQ
Tesla Motors, Inc. (NASDAQ:TSLA)’s shares decreased 3.14% to $219.58. The on July 15 has officially announced the name of its new all-electric vehicle: Model 3. Competing directly against the BMW 3 Series, the Model 3 will go on sale in 2017. The only vehicle Tesla Motors sells right now is the Model S, but it will launch the Model X crossover next year. Tesla Motors CEO Elon Musk said the company was originally planning to name the new vehicle “Model E.”
Why Should You Buy TSLA Now? Get The Free Trend Analysis Here
]]>Get the Inside Scoop On NQ here with this Free Report
SouFun Holdings Ltd. (NYSE:SFUN)’s shares increased 3.75% to $13.23. In a report published on June 12, Deutsche Bank analyst Vivian Hao downgraded SouFun (NYSE: SFUN) from Buy to Hold and lowered the price target to $11.00. The company announced a 40 percent discount on nationwide subscription fee to secondary listing customers, making up approximately 25 percent of revenues. Deutsche Bank sees this as a “major downside surprise for the market,” The analyst sees a magnified de-leveraging impact to its NP due to the higher margin nature of the segment.
You won’t believe what we found out about SFUN
Exelixis, Inc. (NASDAQ:EXEL)’s shares dropped 4.29% to $3.91. The company on July 13 announced positive top-line results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAFV600 mutation. Exelixis’ collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its primary endpoint, delivering a statistically significant increase in progression-free survival (PFS) for the combination of cobimetinib plus vemurafenib as compared to vemurafenib alone.
Why Should You Buy EXEL Now? Get The Free Trend Analysis Here
]]>
Free Urgent Insider Catalyst Report For NQ Available Here
Additionally, the company on Nov. 20 projected record revenues of $305 – 310 million USD for its fiscal year 2014. This exciting forecast was made during the company’s second annual analyst and investor day presentation in New York on November 19, 2013. During the presentation the company also unveiled its 2-5-10 plan, an extension of its 1-2-5 plan introduced at last year’s presentation.
VOXELJET AG (NYSE:VJET) shares declined 1.77% to $37.13. The company on Dec. 3 announced the launch of the latest in its full line of large format industrial 3D printers, the VX2000. The new printer is being demonstrated for the first time at Euromold, the leading worldwide trade fair for Moldmaking and Tooling, Design and Application Development, taking place in Frankfurt, Germany, December 03-06, 2013.
Free Urgent Insider Catalyst Report For VJET Available Here
]]>